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The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in
transplantation and autoimmunity. However, because large cell numbers are needed to
achieve a therapeutic effect, in vitro expansion is required. By comparing their function,
phenotype and transcriptomic profile against ex vivo Tregs, we demonstrate that expanded
human Tregs switch their metabolism to aerobic glycolysis and show enhanced suppressive
function through hypoxia-inducible factor 1-alpha (HIF1A) driven acquisition of CD73
expression. In conjunction with CD39, CD73 expression enables expanded Tregs to convert
ATP to immunosuppressive adenosine. We conclude that for maximum therapeutic benefit,
Treg expansion protocols should be optimised for CD39/CD73 co-expression.
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Regulatory T cells (Tregs) are a subset of CD4
+ T cells that
play an indispensable role in maintaining self-tolerance and
in controlling potentially harmful excessive immune
responses to foreign antigens. They are characterized by surface
expression of the high affinity IL-2 α-chain receptor (CD25), low
expression of the IL-7 α-chain receptor (CD127) and by deme-
thylation at a conserved region within intron 1 of the FOXP3 gene
called the Treg-specific demethylated region (TSDR), leading to
constitutive expression of their master transcription factor FOXP3.
Multiple mechanisms have been proposed for Treg suppressive
function, including: (i) consumption of IL-2; (ii) production of
inhibitory cytokines; (iii) inhibition of antigen presenting cell
maturation and function via the interaction of CTLA4 with
CD80/86 on dendritic cells and (iv) the conversion of proin-
flammatory extracellular ATP to immunoregulatory adenosine
through the action of the surface ectonucleotidases CD39 (ecto-
nucleoside triphosphate diphosphohydrolase-1) and CD73 (ecto-
5’-Nucleotidase). Mechanistically, CD39 degrades ATP into
AMP, which is then hydrolyzed by CD73 into adenosine (ADO).
The importance of ADO mediated suppression for human Tregs
is unclear, as unlike murine Tregs it is generally accepted that
they do not express CD731.
Given the critical role Tregs play in controlling immune
responses, there is a great deal of interest in their therapeutic
potential, particularly in the treatment of autoimmune diseases
and in treating, or preventing, complications from transplantation,
such as graft-versus-host disease (GvHD) following hematopoietic
stem cell transplantation (HSCT), or graft rejection following solid
organ transplantation. Numerous proof-of-principal pre-clinical
studies have demonstrated their efficacy2–5, several phase I/II
studies have demonstrated their safety and tolerability6, and
numerous clinical trials are underway (clinicaltrials.gov and
reviewed7). However, despite their potential, Treg therapy poses a
number of significant challenges, not least of which is cell number.
Tregs make up only 5% of circulating CD4 T cells, therefore
production of therapeutic doses capable of altering immune
responses requires intensive ex vivo expansion. Most protocols
involve broad T-cell receptor (TCR) stimulation of magnetically
separated or flow-sorted Tregs together with provision of IL-2 and
the mTOR inhibitor rapamycin for periods of up to 36 days8.
Rapamycin is an immunosuppressant that forms a gain-of-
function complex with the FK506-binding protein (FKBP12),
which then binds to and inhibits mTOR complex 1 (mTORC1),
inhibiting T-cell proliferation. At low doses, rapamycin pre-
ferentially inhibits T effector (Teff) proliferation, preventing their
outgrowth, so improving Treg purity9.
We and others have previously shown that expanded Tregs
(expTregs) have increased suppressive function when compared to
their ex vivo activated counterparts10–12 but it is unclear why, and
currently there is no consensus on which phenotypic characteristics
best predict therapeutic efficacy. Here we show that acquisition of
CD73, leading to increased CD39/CD73 co-expression and sub-
sequent ability to produce immunosuppressive adenosine from
ATP, best explains the increased suppressive capacity of human
expTregs. Furthermore, we demonstrate that stable CD73 expres-
sion occurs as expTregs switch their metabolism from oxidative
phosphorylation (OXPHOS) to aerobic glycolysis, and that CD73
expression is driven by hypoxia-inducible factor 1-alpha (HIF1A).
Given the clinical importance of optimizing their suppressive
function, we suggest that therapeutic Treg expansion protocols
should be optimized for CD39/CD73 co-expression.
Results
Expanded human Tregs show enhanced suppressive function.
First we expanded flow-sorted CD4+CD25hiCD127lo human
Tregs (Supplementary Fig. 1a) following a standard expansion
protocol used widely for production of Treg cellular therapies
(Fig. 1a), involving two (×2) 14-day cycles of stimulation with anti-
CD3/CD28 beads, in the presence of high-dose IL-2 (500 U/mL)
and low-dose rapamycin (100 nM). As demonstrated by full
demethylation at the FOXP3 TSDR (Fig. 1b) and lack of IL-2
production (Supplementary Fig. 1b) the sorted ex vivo CD4+
CD25hiCD127lo Tregs were highly pure, and the resultant
expTregx2 maintained purity, as shown by HELIOS and FOXP3
co-expression (Fig. 1a), and retained FOXP3 TSDR demethylation
(Fig. 1b).
By day 14, expression of the proliferation marker Ki67 had
returned to baseline (Supplementary Fig. 2a). Taken at this
resting time point, expTreg×2 were found to be significantly more
suppressive than their ex vivo counterparts in an in vitro
suppression assay (Fig. 1c, d). CD4+ CD25hiCD127loCD45RA−
ex vivo memory Tregs (mTregs) were selected as the comparator
to better control for previous activation and memory status
(Supplementary Fig. 2b) and stock pre-labelled allogeneic pan
CD3+ Teffs were used as responders to allow for direct
comparison.
In vivo, expTreg×2 were also significantly more suppressive
than ex vivo CD4+CD25hiCD127lo Tregs when tested in a skin
graft humanized mouse model (median survival time [MST]
>100 days vs 33 days, p= 0.0029, Fig. 1e).
ExpTregs acquire stable CD73 expression during expansion.
We next compared the expression of known Treg-associated
molecules on resting expTregx2 vs. ex vivo mTregs, including:
FOXP3, HELIOS, TIGIT, CD226, CD39, CD73, CD25, CD127
and both intracellular and surface CTLA4. Since expTreg×2 were
larger and more autofluorescent than ex vivo Tregs, the antibody
panel and compensation matrix were optimized for each group
separately (see Supplementary Fig. 3) and the percent positivity of
each target antigen compared. Of these, only CD73 was differ-
entially expressed (mean positivity 4.76% vs. 37.6%; p= 0.0003
Fig. 2a), and thus CD39 and CD73 co-expression was sig-
nificantly higher in resting expTreg×2 compared to ex vivo
mTregs (6.0% vs. 37.9%; p= 0.0027 Fig. 2a). Stimulation of total
ex vivo Tregs (CD4+CD25hiCD127lo) with anti-CD3/28 for 72 h
did not increase CD73/CD39 co-expression; Fig. 2b shows the
acquisition of CD39/CD73 double positivity by expTregs×2 over
two cycles of expansion, compared to ex vivo Tregs and stimu-
lated ex vivo Tregs. Acquisition of CD39/CD73 was similar for
sorted naïve CD25hiCD127loCD45RA+ (nTregs) and mTregs
(Supplementary Fig. 4). CD73/CD39 co-expression was shown to
be stable, surviving freeze/thaw and 2 weeks in culture with low-
dose IL-2 and no additional stimulation (representative plots
shown in Fig. 2c).
Although there is some conflict in the literature, in keeping
with most reports we observed that ex vivo human Tregs
expressed variable levels of CD39 and very little CD73, with only
2.4% (±2.3%) being double positive for CD73 and CD39. This is
in sharp contrast to murine Tregs1, which expressed high levels of
CD73 and CD39 constitutively (64.8 ± 3.5% CD39+/CD73+;
Fig. 2d). As human studies typically involve blood, and murine
studies spleen, we examined immune cells extracted from the
spleen of two deceased human organ donors. This confirmed that
both splenic and peripheral blood-derived human Tregs are
largely CD73 negative, excluding a compartment effect (Fig. 2e).
Next, we flow-sorted highly pure CD39 and CD73 double
negative Tregs from three donors, labelled them with cell division
tracking dye and expanded them in culture as previously
described. CD39 and CD73 expression increased over time with
expansion, ruling out the possibility that expTreg CD39 and
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CD73 co-expression emerges due to the preferential expansion of
small numbers of pre-existing CD39/CD73 double-positive cells.
CD39 expression was gained first. By day 8 (equivalent to 2–3 cell
divisions) approximately 40% of the starting CD39/CD73 double
negative Tregs were positive for CD39, with 25% positive for
CD73. By day 15 CD73 expression had increased in density and
~50% of the starting population had gained expression (Fig. 2f).
By the end of the first cycle of expansion, ~30% of expTregs were
CD39 and CD73 double positive, increasing to 50% by day 28
(Fig. 2g). Tregs expanded from donors with inherent low CD39
expression, correlating with a haplotype tagged by
rs1074864313,14 (CD39loa/a donors, detailed in Supplementary
Fig. 5), still acquired CD39 and CD73 co-expression, but this
required additional rounds of expansion (Fig. 2g). This was due to
delayed acquisition of CD39 rather than CD73 expression
(Supplementary Fig. 5).
PBMC + 5:1 ex vivo Treg (n=4)
PBMC (n=8)
PBMC + 5:1 expTreg (n=5)
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Fig. 1 Therapeutically expanded human Tregs show enhanced suppressive function. a Flow-sorted human Tregs (CD3+CD4+CD25hiCD127lo) were
expanded with anti-CD3/CD28 beads in presence of high-dose IL-2 (500 U/mL) and low-dose rapamycin (100 nM) in 2-week cycles. Representative plots
showing Helios/FoxP3 expression on resting expTreg after two cycles of expansion (expTregx2), gated on live CD4+ T cells. b FOXP3 TSDR demethylation
of flow-sorted human Tregs (CD3+CD4+CD25hiCD127lo) vs. T effectors (Teff), run 1 (n= 2) and ex vivo Treg vs. expanded Treg (expTregs), run 2 (n= 3,
2 female and 1 male donor). c Suppression assay labelling strategy: Flow-sorted ex vivo CD3+CD4+CD25hiCD127loCD45RA− memory Tregs (mTreg) or
resting expTregx2 were labelled with cell division dye V670 (top left plot), and sorted pan T (CD3+) effector cells with proliferation dye V450 (top right
plot), then cultured separately or together (bottom left—ex vivo Tregs; bottom right, expTreg×2) in an in vitro Treg suppression assay ±anti-CD3/
CD28 stimulation. d Summary showing the suppressive function of ex vivo mTregs (orange) vs. expTreg×2 (blue) from four donors at various Teff:Treg
ratios. Line shows the mean percent suppression. n= cells from individual donors, analysed in independent experiments. Compared with ex vivo mTregs,
expTreg×2 were more suppressive at all ratios tested (Two-way ANOVA with Bonferroni multiple testing correction *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001). e In vivo skin graft model, in which mice received a skin graft plus 5 × 106 allogeneic PBMCs together with 1 × 106 ex vivo (orange) Tregs
or 1 × 106 resting expTregs×2 (blue). Data show a Kaplan–Meier survival curve of graft survival (Log-rank test, p-value as shown).
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ExpTregs gain the ability to convert extracellular ATP to
immunosuppressive adenosine, explaining their increased
suppressive function. The coordinated action of the ectonu-
cleotidases CD39 and CD73 converts ATP to immunosuppressive
adenosine in a two-step process; firstly CD39 catalyses the
hydrolysis of ATP to AMP, and secondly CD73 converts AMP to
adenosine (ADO) (Fig. 3a). We confirmed the previously pub-
lished observation that ex vivo nTregs are largely CD39/CD73
double negative1,15,16, in contrast, ex vivo mTregs are either
CD39/CD73 double negative or CD39 single positive (shown by
representative plots, Fig. 3b). To determine the functional con-
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Fig. 2 expTregs acquire stable CD73 expression and become CD39/CD73 co-expressing during their expansion. a Mean percent expression (±1SD) of
Treg-associated markers expressed by resting expTreg×2 (blue bars) and ex vivo mTregs (orange bars) from four donors (multiple t-tests with Holm–Sidak
correction for multiple comparisons). b Representative dotplots of CD39/CD73 co-expression in ex vivo Tregs, stimulated ex vivo Tregs and expTregs.
Percentage expTreg CD39+CD73+ expression in ex vivo Tregs, stim ex vivo Tregs and expTregs from four donors over time (one-way ANOVA followed
by Tukey’s multiple comparison testing). c Top plot: CD39/CD73 expression on flow-sorted expTregs rested for 1 day vs. expTregs rested for 2 weeks
in low-dose IL-2 (50 U/mL). Bottom plot: CD39/CD73 expression on expTregs (red) vs. matched frozen/thawed expTregs (purple). d Percent of
CD4+CD25hiFOXP3+ human (red, n= 10) vs. murine (blue, n= 3) Tregs that are CD39+CD73−, CD39−CD73−, CD39−CD73+ or CD39+CD73+.
A representative dotplot of murine CD39/CD73 expression is shown (multiple unpaired t-tests with Holms Sidak correction for multiple comparisons).
e CD39/CD73 expression on CD4+CD25hi+CD127lo gated Tregs in matched blood and spleen from 2 deceased human donors. f Upregulation of CD39/
CD73 on flow sorted, cell proliferation dye labelled CD39−CD73− DN Tregs at day 8, 12 and 15 post-stimulation (representative plots from 3 donors).
g: Percent CD39+CD73+ co-expression on expTregs from CD39−CD73− DN Tregs from CD39 genotyped donors (CD39+GG/Ga red, n= 4 and
CD39loa/a blue, n= 2). (Two-way ANOVA with Bonferroni correction). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Summary data are presented as
mean ± 1 SD. n represents cells from individual donors, analysed in independent experiments.
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to convert ATP to ADO, we exposed flow-sorted ex vivo nTregs,
mTregs and expTreg×2 from three donors to 50 μM ATP, then
measured AMP and ADO in the supernatant after 1 h by mass
spectrometry. B cells (known to constitutively express CD39 and
CD7317) and monocytes (known to be CD39 single positive18) as
well as CD4 and CD8 Teffs were also assayed. In keeping with
their expression patterns, B cells were the only ex vivo cell type
tested able to produce both AMP and regulatory ADO (Fig. 3c).
CD39 single-positive mTregs and monocytes were able to
produce AMP from ATP, but were not able to convert AMP to
ADO (Fig. 3c). In keeping with their increased co-expression of
CD39/CD73, resting expTreg×2 were high ATP-to-adenosine
converters (~16 fold higher than B cells; Fig. 3c).
To determine if increased production of ADO explains the
enhanced suppressive action of expTregs, we co-cultured anti-
CD3/CD28 activated Teffs, with resting expTreg×2 from three
donors with and without adenosine receptor 2 A blockade



























































Fig. 3 expTregs gain the ability to convert extracellular ATP to immunosuppressive adenosine, which explains their increased suppressive function.
a Schematic showing extracellular ATP conversion to immunosuppressive adenosine (ADO): CD39 converts ATP to AMP then CD73 converts AMP to
ADO, which acts via the adenosine receptor ADR2A on the surface of Teff cells. Created using Biorender.com. b Example dotplots showing differential
expression of CD39 and CD73 in human ex vivo FOXP3+CD45RA+ (naive, nTregs) vs. FOXP3+CD45RA− (memory, mTregs), c Mass spectrometric
measurement of AMP and ADO in cell culture supernatants of various cell types from three donors following addition of 50 μM of ATP. Data shown are
mean of area ratio normalized to matched B cells ±1 SD; one-way ANOVA with Dunnett’s multiple comparison against no cell control. In contrast to naive
and memory ex vivo Tregs, expTreg×2 were able to convert ATP to ADO. d ExpTregs from three donors were cultured with Teffs at a ratio of 8:1
Teffs:Tregs in the absence or presence of ADR2A block ZM 241385 and the percentage suppression at day 5 compared with that of donor-matched ex vivo
Tregs. Bar chart shows combined data for three donors ±1 SD (one-way ANOVA with Tukey’s multiple comparisons test) (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001). Summary data are presented as mean ± 1 SD. n represents cells from individual donors, analysed in independent experiments.
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T cells19,20), and compared their suppressive function with
ex vivo mTregs from the same donors. At a ratio of 8:1
Teffs:Tregs (chosen as a ratio where ex vivo mTregs are
minimally suppressive, whereas expTreg×2 induce 50% suppres-
sion), ADR2A blockade significantly attenuated the suppressive
effect of resting expTreg×2, returning their suppressive capacity to
that obtained with donor-matched ex vivo mTregs (Fig. 3d and
Supplementary Fig. 6). ADR2A blockade had no direct effect on
Teff proliferation (Supplementary Fig. 6).
ExpTregs undergo metabolic remodelling and utilize aerobic
glycolysis during their expansion. To further characterize how
expTregs differ from ex vivo mTregs, transcriptomic analysis was
performed using the Nanostring CAR-T Immune profiling panel,
which quantifies the expression of 780 genes related to T-cell
phenotype, activation and metabolism. RNA was extracted from
ex vivo mTregs and from matched resting expTregs from three
donors after either 2 (expTreg×2) or 5–6 cycles of expansion
(expTreg×5). We detected 85 and 156 genes differentially
expressed between ex vivo mTregs and matched resting
expTreg×2 and expTreg×5, respectively (Fig. 4a and Supplemen-
tary data 1, greater than two-fold difference in expression, FDR
p < 0.05). In expTregs, the majority of the differentially expressed
genes were upregulated (51/85 and 97/156, ex vivo mTregs vs.
expTreg×2 and expTreg×5, respectively). To assess if these genes
clustered in a particular gene network, Gene Set Enrichment
Analysis (GSEA) was performed using the Hallmark and Reac-
tome gene sets and GO_Biological processes. These identified
clear enrichment of metabolic processing in expTreg×2 and
expTreg×5 that included oxidative phosphorylation, glycolysis
and fatty acid metabolic pathways (Hallmark data shown in
Fig. 4b). In addition, enrichment of genes relating to cell division
and biosynthesis was evident (Supplementary data 2).
Next we took resting expTreg×2 and re-stimulated expTre-
g×2restim (8 days post restimulation), and studied their metabo-
lism using a glycolysis stress test with a XF Seahorse extracellular
flux analyser. By assessing the extracellular acidification rates
(ECAR) in response to D-Glucose, as an indicator of aerobic
glycolysis, we found that expTregx2restim were significantly more
glycolytic compared to unstimulated and stimulated ex vivo
mTregs and Teffs (Fig. 4c). We then analysed the concomitant O2
consumption rate (OCR), as a marker of OXPHOS, to assess the
metabolic state of each group (Fig. 4d). We found that the ECAR/
OCR ratio was significantly higher in expTregx2restim compared
to both unstimulated and stimulated ex vivo mTregs, as well as
control Teffs (Fig. 4d). Overall, these data demonstrate that upon
stimulation expTreg cells increase glycolysis, which they pre-
ferentially use over OXPHOS. In keeping, extracellular lactate (a
by-product of glycolysis) was found to accumulate in the cell
culture supernatant of expTregs, and this correlated with
increasing expTreg numbers (Fig. 4e).
For two of the three donors studied, expTreg×2restim were also
available for Nanostring analysis. This demonstrated further
increased expression of genes involved in oxidative metabolism
and glycolysis (Fig. 4b), and the second most differentially
expressed gene was the master transcriptional regulator of the
adaptive response to hypoxia HIF1A, which doubled in expres-
sion upon restimulation (Fig. 4f; Supplementary data 1). No
significant difference in HIF1A expression was seen between
resting expTregs and ex vivo mTregs suggesting transient HIF1A
upregulation during proliferation. Under hypoxic conditions—
but also in the setting of aerobic glycolysis and mTORC1
signalling21–23 - HIF1A activates the transcription of over 100
genes including glucose transporters, glycolytic enzymes and also
CD73 (NT5E)24–27 (reported HIF1A responsive genes captured
by the CAR-T Nanostring panel are shown in Supplementary
Fig. 7). This suggested a potential role for HIF1A signalling in
CD73/NT5E upregulation in our metabolically active, proliferat-
ing expTregs.
CD73 upregulation in human Tregs can be achieved by stabi-
lization of HIF1A. Under resting/aerobic conditions HIF1A is
constitutively degraded by the Von Hippel-Lindau (VHL)
mediated ubiquitin protease pathway. Therefore, to determine if
CD73 Treg expression could be induced by the post-translational
stabilization of HIF1A, we cultured PBMCs for 30 h, in normoxic
conditions (21% oxygen), with and without the addition of the
VHL blocker VH29828. In the presence of VHL blockade, Treg
CD73 expression increased significantly, with increases in both
the percentage of CD73+ Tregs, and density of CD73 expression
observed (Fig. 5a). Given the dependence of CD73 upregulation
on HIF1A we hypothesized that Tregs expanded without rapa-
mycin (an mTor and therefore HIF1A inhibitor) may upregulate
CD73 more efficiently. In keeping with this, removing rapamycin
increased the expansion rate and gain of CD39/CD73 co-
expression in expTregs (Fig. 5b–e).
CD39/CD73 co-expression is unrelated to loss of CD27 and
gain of CD70. We have previously reported that with prolonged
Treg expansion a population of dysfunction Tregs emerge,
characterized by loss of CD27 and gain of CD70 expression29.
Therefore, we investigated the relationship between CD27, CD70,
CD39 and CD73 expression on Tregs expanded for 5–6 cycles
(expTreg×5–6) by flow cytometry. Although the CD27−CD70+
and CD39+CD73+ populations were not mutually exclusive,
significantly fewer CD27−CD70+ cells were found within in the
CD39/CD73 double-positive subpopulation compared to non-
double-positive cells (Fig. 6a), and fewer CD39+CD73+ double-
positive cells were found within the CD27−CD70+ gate com-
pared to the remainder of the expTregs (Fig. 6b).
Multiple rounds of Treg expansion leads to reduced TCR
diversity. Given that individuals with inherent low CD39
expression require additional rounds of proliferation to gain
CD39/CD73 co-expression, we determined how prolonged
expansion might affect Treg TCR clonal diversity. TCR diversity
was assessed by measuring the expression of the 45 TCR alpha
and 46 TCR beta chain probes included in the Nanostring CAR-T
panel on ex vivo mTregs and expTregs from the same donor.
TCR diversity was similar between ex vivo mTregs and
expTreg×2, but with additional expansion cycles (expTreg×5–6),
TCR diversity decreased, suggesting the outgrowth of a few
dominant clones (ex vivo vs. expTreg, p= 0.03, Fig. 6c). The
specific alpha and beta chains that became dominant varied from
donor to donor (Supplementary Fig. 7). To investigate the rela-
tionship between gain in CD39/CD73 co-expression and reduced
clonal diversity in late expanded Tregs, we flow-sorted CD39/
CD73 double-positive (DP) expTregs and non-double-positive
(non-DP) expTregs—no difference in TCR clonality was seen
between the two groups (Fig. 6d and Supplementary data 1).
Discussion
In this study we have shown that human expTregs, expanded
in vitro using a typical clinical expansion protocol (involving
anti-CD3/CD28 stimulation in the presence of high-dose IL-2
and ±low-dose rapamycin), gain super-suppressive function
in vitro and in vivo, at least in part due to the upregulation of
CD73, leading to their enhanced ability to convert extracellular
ATP to immunoregulatory adenosine. The result of our work has
significant implications for therapeutic Treg expansion protocols
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and for the phenotypic testing of expTregs prior to adoptive
transfer. As the number of trials testing Tregs increases,
there is a desire amongst the community to develop a standar-
dized framework for describing their isolation, generation,
storage and phenotypic characterization prior to adoptive
transfer30. We strongly suggest that CD39/CD73 co-expression
is included in this “minimum information about Tregs”
(“MITREG”) dataset.
Tregs are a subpopulation of CD4 T cells that are critical in
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Fig. 4 ExpTregs undergo metabolic remodelling and utilize aerobic glycolysis during their expansion. a Volcano plots of differential gene expression
between ex vivo mTregs and resting expTregs (after 2 or 5/6 cycles) measured using Nanostring CAR-T panel. Gene Set Enrichment Analysis (GSEA)
using the Hallmark pathways showed enrichment of metabolic genes (filled triangles). b Heatmap showing differential expression of genes involved in
glycolysis, fatty acid metabolism and oxidative phosphorylation between ex vivo mTregs, resting expTregs (after 2 or 5/6 cycles) and re-stimulated
expTregs (mid-cycle 3). c Representative glycolysis stress test of resting expTregs×2 and re-stimulated expTregs×2restim from the same donor showing
Extracellular Acidification Rate (ECAR) changes (left plot). Oligo oligomycin, 2DG 2-Deoxy-D-glucose. Single technical replicates (≥3) are shown as light
lines, mean values are shown as dotted dark lines. Two-way ANOVA. Right plot shows histogram of ECAR values after D-Glucose in ex vivo mTregs,
expTregs×2 and Teffs (unstimulated and stimulated). Single donors (≥2) are shown as circles, bar graphs show mean values ± SEM. One-way ANOVA.
dMetabolic state of each group according to the Oxygen Consumption Rate (OCR) and ECAR after D-Glucose (left plot). Single donors (≥2) are shown as
light circles, mean values are shown as dark squares. ECAR/OCR ratio as indicator of preferential use of glycolysis over OXPHOS (right plot). Single donors
(≥2) are shown as circles, bar graphs show mean values ± SEM. One-way ANOVA. e Lactate in the cell supernatant of expTregs, measured
spectrophotometrically, correlated positively with cell number (R2.0.89, p= 0.05). f HIF1A expression increased two-fold in expTreg×2 compared to
matched ex vivo Tregs. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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expression of CD25 and low expression of CD127, neither of
which are specific to Tregs, and by demethylation of the TSDR
(which is considered to be the “gold-standard” for identifying a
Treg) which leads to constitutive expression of their master
transcription factor FOXP331. FOXP3 controls many aspects of
Treg biology, including their development, transcriptional pro-
gramme and suppressive function32, and loss-of-function muta-
tions in FOXP3 cause lethal autoimmunity in both mice and
humans33,34.
As we and others have previously reported10–12, expTregs were
found to be super-suppressive when compared to matched
ex vivo Tregs. This was demonstrated using a standard in vitro
suppression assay and in a humanized mouse model of skin
transplantation. Humanized mouse models are powerful pre-
clinical tools for studying the in vivo effectiveness of human Treg
populations35,36. In this study we co-transferred ex vivo and
expTreg×2 at a ratio of 1:5 Tregs to PBMCs, a ratio selected based



















Fig. 5 CD73 upregulation in human Tregs can be achieved by stabilization of HIF1A, and is gained more rapidly in the absence of rapamycin.
a Percentage of CD73+ cells and MFI (geometric mean fluorescent intensity) of CD73 on ex vivo CD3+CD4+CD25hiCD127lo Tregs from 4 donors as
measured by flow cytometry following 30 h of culture with and without VH298 at 200, 100 and 50 μM. Increased CD73 was observed between the
200 μM concentration and untreated cells both for % CD73 and MFI. Example histogram from one donor shown on left. (One-way ANOVA with Dunnett’s
correction). b Percentage CD39+CD73+ co-expression in expTregs cultured in the presence and absence of rapamycin after one round of expansion (three
donors, one-way ANOVA followed by Tukey’s multiple comparison testing). c Representative example of CD39/CD73 co-expression in expTregs cultured
with and without rapamycin. d Rate of expansion (fold change) in expTregs cultured with and without rapamycin (three donors, two-tailed paired t-test).
e Rate of expansion vs gain of CD39/CD73 co-expression in expTregs (Pearson’s rank r= 0.875). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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dose that would be most sensitive for demonstrating suppressive
differences10. At this dose, ex vivo Tregs failed to enhance graft
survival, whereas resting expTregx2 led to long-term (>100 day)
graft survival in 4 out of 5 animals tested.
Next, expression of Treg-associated markers was examined by
flow cytometry. Using a predefined and therefore restricted panel,
only CD73 was significantly upregulated on expTreg×2 vs. mat-
ched ex vivo mTregs (~8-fold change), leading to an increase in
CD39/CD73 double-positive Tregs. Ex vivo mTregs were selected
as the comparator to better control for previous activation and
memory status. CD39, a member of the ectonucleoside tripho-
sphate diphosphohydrolase (E-NTPDase) family, converts ATP
to AMP, which is then hydrolyzed to immunoregulatory adeno-
sine by CD7337. Accumulated extracellular adenosine then binds
to its receptor (A2AR) on the surface of Teffs. Signals induced by


















































































































































































































































































































































































































Fig. 6 Multiple rounds of Treg expansion leads to reduced TCR diversity. a Analysis of CD27−CD70+ expTregs within gated CD39/CD73 double-
positive expTregs and non-double-positive expTregs. Gating strategy is shown for one representative donor and summary data for three donors. b Analysis
of CD39/CD73 co-expression within CD27−CD70+ expTregs and non-CD27−CD70+ expTregs. Gating strategy is shown for one representative donor
and summary data for three donors. One-way ANOVA followed by Tukey’s multiple comparison testing. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
c Expression of TCR alpha and TCR beta variable chains in expTreg×2 and expTreg×5–6 relative to their ex vivo mTreg counterpart (n= 3 donors, left plots.
Red error bars show median with 95% CI, dotted green line denotes the mean of the ex vivo data set).TCR clonality is reduced in expTregs×5–6 as the mean
expression of all alpha or beta chains is below zero, whereas only a few dominant TCR chains are expanded (values above zero). Log2 counts are shown in
Supplementary Fig. 7. TCR clonality score of ex vivo mTregs vs. expTregs after 2 or 5–6 cycles of expansion (n= 3 donors, right plot) calculated using the
expression of the variable TCR beta chain. d TCR clonality of sorted CD39+CD73+ double positive (DP Tregs) vs non-double-positive Tregs in two donors
and TCR clonality score calculated using expression of the variable TCR beta chain.
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several cellular functions, such as T-cell proliferation and cyto-
kine production15,19. Although there is some conflict in the
literature38, it is generally accepted that human Tregs do not
constitutively express CD731, leading some to hypothesize that, in
humans, adenosine-mediated suppression involving Tregs may
depend upon paracrine mechanisms requiring the close proximity
of CD39+Tregs to other cells expressing CD73 or other
ectoenzymes16,39. Here we provide evidence for an additional/
alternative explanation, i.e. that human Tregs do acquire the full
enzymatic machinery to generate adenosine (as demonstrated
here by mass spectrometry), but only after proliferation. In sup-
port of this, proliferating ICOS+ Tregs in melanoma patients
treated with high-dose IL-2 have been reported to co-express high
levels of CD73 and CD3940. Failure to observe CD73 even on
stimulated ex vivo Tregs may be an artefact of their anergy
in vitro. Using an ADR2A blocker we confirmed that increased
adenosine production was sufficient to explain the increased
suppressive function of expTregs in vitro. Due to constraints
imposed by low ex vivo Treg numbers, and to ensure sufficient
technical repeats, this assay was only performed at one ratio;
however, our data clearly demonstrate that production of
immunosuppressive adenosine is an important regulatory
mechanism gained by expanded Tregs. As this assay involved
culturing Teffs with anti-CD3/CD28 beads, plus or minus the
addition of Tregs, it confirms a direct effect on Teff cells, but may
have missed additional enhanced suppressive mechanisms
involving antigen presenting cells.
CD73 expression increased late, after several rounds of cell
division, perhaps reflecting the importance of this pathway in
switching off immune responses rather than preventing immune
activation. However, once acquired, CD73 expression was found
to be stable in vitro (at least up to 2 weeks) and to survive freeze/
thawing. These are both important attributes when considering
the practicalities of giving expTregs therapeutically. While per-
forming these experiments, we observed high inter-individual
variation in Treg CD39 expression, which has previously been
reported13,14, and CD39 expression correlated with a haplotype
tagged by rs10748643, with reduced CD39 expression from the A
allele. Repeated stimulation and cell division could overcome this
genotypic effect, but took up to 60 days in the CD39loa/a donors
tested; this is in keeping with previous reports41. Given how
common the rs10748643 A allele is globally (32.8% in Latino to
76.5% in East Asians42), CD39 genotype should be considered in
therapeutic Treg expansion protocols, which may need to be
extended in CD39loa/a individuals if full therapeutic gain is to be
achieved. However, this will need to be balanced against the
potential for exhaustion with repetitive rounds of stimulation43,
including the emergence of a CD27−CD70+ dysfunctional
population29 and against loss of clonal diversity. However, as
shown, the CD73/CD39 double-positive population are neither
enriched for CD27−CD70+ cells, nor less diverse than their non
CD73/CD39 counterparts.
Transcriptome analysis of ex vivo mTregs and expTregs
showed clear enrichment of genes involved in metabolic proces-
sing, including glycolysis, OXPHOS and fatty acid metabolism.
OXPHOS involves intermediates from glucose, fatty acids, and
amino acids, entering the oxygen-dependent tricarboxylic acid
(TCA) cycle and electron transport chain (ETC) in mitochondria.
In glycolysis, glucose is metabolized to pyruvate, which is con-
verted into lactate rather than entering the TCA cycle. This is a
rapid but less efficient way of producing ATP from glucose that is
not dependent upon oxygen44; in addition it produces a pool of
intermediate catabolites that can be utilized in other anabolic
pathways, such as the pentose phosphate and serine
pathways45,46. In keeping with this, GO term analysis demon-
strated enrichment of biosynthetic pathways in expTregs.
Although Nanostring is a highly sensitive and robust platform, as
it is targeted we may have missed important changes in other
pathways not captured by the panel.
Next, using a Seahorse XF extracellular flux analyser we
assessed ECAR and OCR as surrogate measures of glycolysis and
OXPHOS. In keeping with the literature, in response to activation
Teffs upregulated both OXPHOS and glycolysis despite sufficient
oxygen; aerobic glycolysis is well described in Teffs47,48. On the
contrary, and in keeping with their anergic state in vitro, sti-
mulated ex vivo mTregs did not significantly alter their meta-
bolism. However, resting expTreg×2 demonstrated high levels of
OXPHOS and aerobic glycolysis, and further shifted their meta-
bolism to aerobic glycolysis on restimulation, resulting in the
accumulation of lactate. Aerobic glycolysis is induced by the
activation of the protein kinase B (Akt)/mammalian target of
rapamycin complex 1 (mTORC1) signalling pathway, and by
subsequent activation of the HIF1A which binds to response
elements in target genes, including genes encoding glucose
transporters and glycolytic enzymes21–23. In keeping with our
data, HIF1A increases the abundance of lactate dehydrogenase
(LDH), which catalyses the conversion of pyruvate to lactate,
thereby limiting production of acetyl-CoA for the TCA cycle. It
also increases pyruvate dehydrogenase kinase (PDK) leading to
the inhibition of pyruvate dehydrogenase (PD) which converts
pyruvate into acetyl-CoA.
While aerobic glycolysis is well described in activated Teffs, the
role of glycolysis in Tregs is more contentious, with a number of
recent papers challenging the dogma that Tregs depend largely on
fatty acid oxidation49,50. For example, while Treg induction is
enhanced by low mTOR signalling and inhibition of
glycolysis51–54, mTORC1-deleted Tregs show impaired suppres-
sive function in vitro and the mice developed a scurfy-like
phenotype55,56 due to the loss of metabolic homeostasis in TCR-
activated Tregs, reflected by reduced production of glucose-
derived lipids and nucleotides and downregulated expression of
mitochondrial genes56–59. Furthermore, glycolysis and HIF1A
have been shown to be important in supporting the high meta-
bolic demand of Treg migration, both in vitro and in vivo60,61. In
addition to these predominantly murine studies, human Tregs
have recently been shown to switch to glycolysis following TNF
receptor 2 induced proliferation62, and recent proteomic analysis
of human Tregs has provided further evidence of the importance
of glycolysis in human Treg biology63. Taken together, our
Nanostring and Seahorse data support the concept that, despite
being cultured in low-dose rapamycin, rapidly expanding human
Tregs undergo metabolic remodelling and a shift to aerobic gly-
colysis in response to TCR stimulation in the presence of IL-2,
which sustains cell expansion, division and biosynthesis, as has
been reported for Teffs.
By binding to a responsive element in the CD73 promotor,
stabilized HIF1A has been reported to increase CD73 expression
in human intestinal epithelial cells24 and breast cancer cell lines25,
raising the possibility that increased expTreg CD73 expression
may be intrinsically linked to their altered metabolic state, and
potentially driven by HIF1A. To explore this we stabilized HIF1A
using the VHL blocker, VH298. In normoxic/resting conditions
HIF1A is constitutively degraded by the VHL mediated ubiquitin
protease pathway. In contrast to several chemical agents known
to stabilize HIF1A, such as Fe2+ substitutes and inhibitors of
prolyl hydroxylase domain enzymes, VH298 is highly specific,
capable of upregulating HIF1A-target genes, with no “off target”
effects28. This confirmed that VHL blockade with VH298 was
sufficient to increase expression of CD73 surface protein
expression on human Tregs, with increases in both percentage
positivity and density of expression. Interestingly, whilst glyco-
lysis/HIF1A signalling is required to upregulate CD73, it appears
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expTregs do not need to be in a continued state of glycolysis to
maintain CD73 at the cell surface.
Due to its relative specificity for suppressing the outgrowth of
T effectors vs Tregs, the mTOR inhibitor rapamycin is commonly
used to increase the purity of expTregs cultures. Our data
demonstrate HIF1A drives acquisition of CD73 and therefore
expTregs gain CD39/73 more rapidly in the absence of rapamy-
cin, raising the question as to whether therapeutic Tregs should
be expanded without rapamycin. However, as this will affect the
purity of the final product, the decision to exclude rapamycin will
depend on the purity of the starting population, for example it is
likely to be required for magnetic bead isolated Tregs where the
starting purity is relatively low.
With repeated rounds of expansion, required for gain of CD39/
CD73 co-expression, TCR diversity reduced (although the CD39/
CD73 double-positive subpopulation was no less diverse than the
bulk population). Although Tregs can efficiently suppress poly-
clonal autoreactive responses through non-specific bystander
suppression, and can recruit additional regulatory cell popula-
tions through “infectious tolerance”, it has been shown that TCR-
restricted Tregs are less able to control murine GvHD, when
compared to TCR-diverse Tregs64. In the same study, restricted
Tregs were fully able to suppress anti-CD3 responses in vitro,
suggesting that decreased in vivo suppression related to the
probability of Treg activation, rather than a qualitative suppres-
sive defect in the Tregs themselves. A limitation of our work is
that Nanostring cannot assess true clonality, which can only be
determined using the full sequence of the TCR, but rather esti-
mates clonality as a function of TCR beta variable region
expression.
In conclusion, using a standard therapeutic protocol, we have
shown that human expTregs switch their metabolism from
OXPHOS to aerobic glycolysis to meet the bioenergetic demands
of expansion and proliferation. Associated HIF1A signalling
promotes surface CD73 expression which, with CD39, provides
expTregs with the full enzymatic machinery to convert ATP to
immunoregulatory adenosine, leading to their enhanced sup-
pressive function. We suggest that Treg expansion protocols
should be optimized for CD39/CD73 co-expression and should
take into account the additional time required for CD39loa/a
individuals to gain expression if maximum therapeutic effect is to
be achieved. This may need to be balanced against the need to
retain clonal diversity.
Methods
Ethics statement. All work was completed under ethically approved studies.
Human PBMCs were isolated from healthy volunteers after obtaining fully
informed consent under CAMSAFE (REC-11/33/0007) or from buffy coats or
leukocyte cones from healthy blood donors (NHSBT, UK). Human spleen was
obtained from two deceased organ donors via the Cambridge Bioresource for
Translational Medicine (CBTM) (REC 15/EE/0152 REC: East of England-Central
Cambridge Research Committee). Healthy skin and blood was donated from
patients undergoing plastic surgery procedures as previously described36 and
with full informed consent under approval number 07/H0605/130 from the
Oxfordshire Research Ethics Committee B. All mice were treated in strict accor-
dance to the UK Animals (Scientific Procedures) Act of 1986 and under PPLs
P8869535A or PPL80/8970.
Cell isolation and magnetic separation. Human PBMC were isolated from
heparinized blood, and splenic mononuclear cells (SMNCs) were isolated from
mechanically dissociated and filtered human and murine spleens (from C57BL/6
mice) using Ficoll density gradient centrifugation (Ficoll PaquePlus; GE Health-
care, Amersham). CD19+ B cells, CD14+ monocytes and CD4+ T cells were
isolated by positive magnetic selection (Miltenyi Biotec). Prior to flow sorting
Tregs, untouched Pan T cells were enriched by negative selection using T-cell
isolation kit II (Miltenyi biotec).
Flow phenotyping and flow sorting. Cells were stained using a range of antibodies
(BD, ebioscience, Biolegend) at 1:50 dilution unless otherwise stated, and blocked
using 2% mouse serum (or 1% FCS for murine cells) in Facs buffer and/or Tru
block monocyte blocker (Biolegend) as required. Intracellular staining was per-
formed using the FOXP3 permeabilization staining kit (Invitrogen) for 45 min at
room temperature followed by staining of intracellular markers in 1× perm wash
buffer for 45 min at room temperature. Cell sorting was performed on either a
FACS Aria (BD) or Influx (BD) cell sorter. Flow acquisition for phenotyping was
performed on the Canto II or Fortessa LSR (BD Biosciences) and analysed using
FlowJo v7.6.5-v10.0 (Tree Star Inc). Gating strategies and control staining are
shown within each figure and additional control staining for CD73 and FOXP3 are
shown in Supplementary Fig. 8.
Ex vivo Treg isolation and expansion. Human ex vivo CD127loCD25+CD4+
Tregs were flow sorted using a BD FACSAria cell sorter (BD Biosciences) after
staining with: CD39-BB515 (clone Tu66, BD), CD25-PE (clone MA251, BD) or
CD25-PE (BD), CD4 APCFire/750 (Clone A161A1, Biolegend) or CD4-ECD
(Clone SFCI12T4D11, Beckman Coulter), CD73-BV421 (clone AD2, Biolegend),
CD8 V500 (RPA-T8, BD), CD3-BV605 (SK7, Biolegend), CD127-AF647 (clone
HIL-7R-M21, BD) or CD127-PEcy7 (eBioRDR5, ebioscience/Thermofisher) and
CD45RA-BV786 (clone Hi100, BD), then expanded with 500–1000 U/mL human
rIL2 (Miltenyi Biotec/Chiron) ±100 nM rapamycin (Miltenyi Biotec) and human
Treg expansion kit anti-CD3/CD28 beads (Miltenyi Biotec/Invitrogen), using
x-vivo 15 cell medium (Lonza) or RMPI-1640 medium supplemented with L-
glutamine, penicillin-streptomycin (both PAA Laboratories, UK), sodium pyruvate
(Gibco, UK) and 2–10% human AB pooled serum and media exchanged with fresh
IL-2 every 3–5 days. For additional experiments, either memory Tregs (mTregs)
were sorted as CD4+CD25+CD127loCD45RA−, naïve Tregs were sorted as
CD4+CD25+CD127loCD45RA+ or CD39−CD73− double negative Tregs were
sorted as CD4+CD25+CD127loCD39−CD73−. Beads were removed using MAC-
Sibead magnet (Milteny Biotec) prior to phenotyping or use in functional assays.
Example sorts shown in Supplementary Figs. 1a and 2b).
Measurement of FOXP3 TSDR methylation. The methylation status of the
FOXP3 TSDR was measured using the protocol previously described65. In brief,
expTregs were processed with the Qiagen Epitect Fast Bisulfite kit, which lyses the
cells and performs the bisulfite conversion in a single step. First round PCR tar-
geted 9 CpG sites within the FOXP3 TSDR and a second round PCR added index
sequences and illumina compatible ends allowing for sequencing on an Illumina
MiSeq (2 × 300 bp reads). The percent FOXP3 demethylation was calculated as the
proportion of sequencing reads containing 8 or 9 of the CpG sites within the TSDR
being demethylated compared to the total number of sequencing reads. For female
donors TSDR demethylation values were multiplied by two to account for the fact
that one X chromosome is fully methylated due to X inactivation This required
because FOXP3 is located on the X chromosome. Since there is a known bias in
PCR efficiency of demethylated DNA66,67 this leads to values of over 100% in
female donors.
In vitro stimulation and suppression assays. For short term activation of sorted
Tregs and Teffs, cells were cultured in RPMI complete media containing 10% FCS,
Penicillin-streptomycin and Hepes ± anti-CD3/CD28 stimulation (Invitrogen
dynabeads) at a cell:bead ratio of 4:1. In vitro suppression assays were performed as
previously described68, briefly: Cell tracker V670 (invitrogen) labelled Tregs
(ex vivo or expanded) and cell tracker V450 (Invitrogen) labelled MACS sorted Pan
T cells (Miltenyi T-cell isolation kit II) were co-cultured in 96 V bottom plates
(Greiner). Pan Teffs were seeded at 2 × 104 cells per well in RPMI+ 3% human AB
serum in the absence or presence of equal and titrated numbers of Tregs and
stimulated using Miltenyi Tregs suppression inspector beads according to the
manufacturer’s instructions. Stocks of allogeneic pan Teffs pre-labelled with V450
cell tracker dye were frozen in liquid nitrogen and used as standard Teffs for these
assays. Assays were performed alone or in the presence of 2.5 μM ZM 241385
(Sigma)—a selective ADR2A antagonist. Proliferation was measured on day 4–5
using BD fortessa HTS plate reader. V670+ Tregs were gated out to enable analysis
of the effector population (CD4+V450+V670− cells) and suppression was calcu-
lated by taking the ratio between the proliferating and non-proliferating popula-
tions as previously described68.
Skin allograft suppression assay model. Immunodeficient BALB/c Rag2−/−
IL2rg−/− mice were purchased from Jackson Laboratories (Maine, USA) and
housed under specific pathogen-free conditions in the Biomedical Services Unit at
the John Radcliffe Hospital (Oxford, UK). Mice between ages of 6 and 12 weeks
were used. Skin grafting was performed as previously described36. Briefly, 1 × 1 cm
piece of human skin was fashioned and sutured to the mouse recipient skin on the
left dorsal thorax over the costal margin. Grafts were left to heal for 35 days, before
receiving an intraperitoneal injection of 5 × 106 human peripheral blood mono-
nuclear cells (PBMCs) allogeneic to the graft donor. Skin grafts were monitored
regularly until loss. In experimental groups with Treg cells, 1 × 106 Tregs from the
same donor as PBMCs were co-injected with PBMCs. In all mice the degree of
human leukocyte reconstitution was measured by flow cytometry at the time of
harvest. Mice with human leukocyte chimerism levels of >0.1% in the blood or >1%
in the spleen were defined as reconstituted and included in the study36. Skin
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allograft survival time was calculated from the point of PBMC injection to the point
of complete graft loss/visible rejection.
Functional metabolite assays (Mass Spectrometry). The ability of different
populations of cells to metabolize ATP to ADP, AMP and adenosine (and from
AMP to adenosine) was measured using an ATP and AMP hydrolysis Mass
Spectrometry protocol69. Briefly, cells of interest were isolated by either MACS or
flow sorting and then separately cultured at 2 × 104 cells/well in triplicate in 96-well
plates at 37 °C in 5% CO2 for 1 h, in the presence or absence of 50 μM ATP or
AMP. Cells were pelleted and supernatants flash frozen in liquid nitrogen and
stored at −80 °C. Wells containing no cells and wells containing cells with no
added ATP/AMP were used as controls. Supernatants were thawed and metabolites
extracted using 2:1 methanol/chloroform followed by 1:1 water and chloroform.
Nucleotides were measured by Liquid Chromatography tandem Mass Spectro-
metry (LC-MS/MS) using a Thermo Quantiva interfaced with a Ultra High per-
formance Liquid Chromatography (UHPLC) Vanquish system (Thermo Scientific,
Hemel Hempstead, UK). For chromatography on the UHPLC system, the strong
mobile phase (A) was 100 mM ammonium acetate, the weak mobile phase was
acetonitrile (B) and the LC column used was the ZIC-HILIC column from Sequant
(100 × 2.1 mm, 5 µm). Relative abundance of each metabolite was measured as area
under the curve at relevant masses and normalized to stable isotope labelled
standards.
Metabolism assays (Seahorse XF extracellular flux assay). Oxygen con-
sumption rates (OCR) and extracellular acidification rates (ECAR) were measured
using a 96-well XF extracellular flux analyzer (EFA) (Seahorse Bioscience). Once
isolated cells were seeded in assay medium (Agilent Seahorse XF RPMI Medium
pH 7.4 cat no. 103576-100, containing 1 mM HEPES, and 2 mM Gibco Glutamax
cat no. 35050-038) on a 96-well XF plate, pre-coated with Cell-Tak solution
(Corning 354240, 3.5 ug/cm2 of surface area), at a concentration of 50,000/100,000
cells per well. After centrifugation at 200 × g for 1 min (zero braking), cells were left
to rest in a 5% CO2 incubator at 37 °C for 30 min. Medium was exchanged and the
plate was then incubated in a non-CO2 incubator at 37 °C for 1 h. A Glycolysis
stress test was then performed by adding D-Glucose (final concentration 10 mM),
oligomycin (final concentration 2.5 μM) and 2DG (final concentration 50 mM).
After the run, cells were fixed with 4% PFA for 10 min and incubated with 1:10,000
DAPI. Data from were then normalized on the DAPI+ area averaged from 4 ROIs
(×10 objective) for each well. Quality control for each well was performed on pH
and oxygen flux, and wells that were not reliable were removed from further
analysis, according to manufacturer’s instructions. The glycolytic values were cal-
culated as the ECAR after addition of D-Glucose, while the OXPHOS values were
calculated based on the OCR after addition of D-Glucose. The metabolic state of
each group was calculated as the glycolytic value divided by the OXPHOS value.
Lactate measurements. Extracellular lactate was measured in cell culture super-
natants as a read out of glycolytic activity. Supernatants were collected at various
timepoints during expTreg expansion and stored at −20 °C until required. Lactate
was measured as previously described68, briefly: lactate was measured spectro-
photometrically using a Dimension EXL autoanalyser (Siemens, Germany) with
Flex© reagent cartridges (product code DF16). Lactate dehydrogenase (LDH, 40U),
Nicotinamide adenine dinucleotide (NAD, 10 mmolL-1), dihydrazine sulphate
(10 mmolL-1) and tris buffer (100 mmolL-1) were added to cell free expTreg
expansion supernatants. The subsequent exchange of lactate to pyruvate, captured
by the dihydrazine compound, is directly proportional to the change in NAD+ to
NADH concentration measured at 340–383 nm, from which the initial lactate pool
size was inferred.
Transcriptomic profiling by Nanostring. 100,000 freshly-sorted ex vivo mTregs
and 100,000 resting, expanded Tregs from the same donors were harvested and
washed twice in PBS, cells pelleted and lysed in RLT buffer (Qiagen). For the
expanded Tregs, samples were taken after 2 rounds of expansion (expTregx2) and
after 5–6 rounds of expansion (expTreg×5–6). In addition, for 2 of the 3 donors,
additional RNA was extracted mid-cycle 3, when >50% of the cells were in cycle
(>50% Ki67+). RNA was extracted using Qiagen RNeasy micro kit and their
transcriptome measured using the nanostring CAR-T characterization panel
(Nanostring technologies) using an nCounter prep station and digital analyser; the
Nanostring CAR-T panel measures the expression of 780 genes, that includes genes
to characterize cell phenotype, activation state, metabolism, exhaustion and TCR
diversity.
Statistics and reproducibility. All flow cytometry data were analysed using
FlowJo (version 10). Statistical tests were performed using Graphpad Prism
6.0 software (GraphPad Software Inc, California). Survival data were analyzed
using log-rank tests. Comparisons between groups of three or more were compared
using a one-way ANOVA with Tukey’s or Dunnet’s post-hoc multiple comparisons
tests, as indicated. Comparisons of two groups were tested with either one-tailed or
two-tailed Student’s t-tests, a two-way ANOVA with Bonferroni post-hoc multiple
comparisons test, or multiple t-tests with Holm–Sidak post-hoc correction as
appropriate. For Seahorse analysis comparisons between groups were calculated
using one-way ANOVA followed by unpaired two-tailed Student’s t-tests. XF
extracellular flux assay data were analysed by two-way ANOVA followed by Sidak’s
multiple comparisons test, or one-way ANOVA followed by Tukey’s multiple
comparison test, as appropriate. Comparisons over time were calculated using two-
way ANOVA followed by Bonferroni’s multiple comparison tests. Lactate con-
centration was compared with expTreg number using a linear correlation (Data
processed in Matlab 2017a, The Mathworks, MA). The number of biological
replicates for each dataset are given in figure legend. All biological data points were
derived from at least two technical replicates.
Nanostring data were normalized using nsolver 4.0 software (Nanostring),
background thresholding was performed at the mean+ 2SD of the negative probe
values for each sample (range 15.2–36.4). Only probes with counts greater than the
background threshold in at least two of the three samples were included in the
analysis. Volcano plots were generated using the EnhancedVolcano R package70
and heatmaps were visualized with the Bioinfokit python package71. The Geneset
enrichment analysis (GSEA) tool72 was used to determine if there was enrichment
of any hallmark pathways73 between the ex vivo and expTregs. The Nanostring
CAR-T panel contains probes to 45 TCR Alpha and 46 TCR beta variable chains,
Briefly, the variable regions were assessed for overall expression and normalized to
a panel standard, which allowed for more precise quantification. As an estimate of
TCR diversity, a TCR clonality score was determined using the Shannon Diversity
index calculation, a measure of species diversity in a community. This ecological
measurement was used to account for the abundance and evenness of the T-cell
beta variable regions present within a given sample versus the population of T-cell
receptors within a given dataset. The score given is relative—a higher TCR score
means a more diverse population of variable regions, and a less clonal population,
whereas a lower score means less diversity, and a more clonal population.
Genotyping. Donors were genotyped for SNP rs10748643, which is located within
intron 1 of ENTPD1, the gene encoding CD39. Primers were designed that flank
the variant (forward—GCACAGATGGTGTGCAGTCT, reverse—
TCTTCCTGGCTCTCACACG), and PCR was performed to amplify this region
using a 16 µl reaction containing 8 µl of Qiagen Multiplex PCR master mix, 0.5 µl
of each forward and reverse primers (10 µM), 5 µl water and 2 µl of genomic DNA
(5 ng/µl). The PCR cycling conditions consisted of 15 min hotstart at 95 °C, fol-
lowed by 30 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds and 72 °C for
30 seconds. The 97 bp PCR amplicon was digested with the restriction enzyme
SCRF1 (New England Biolabs), and visualized on the Agilent Bioanalyser. The
SCRF1 cuts the PCR amplicon to generate 90 and 7 bp products if homozygous for
the A allele; 52, 38 and 7 bp products if homozygous for the G allele and 90, 52, 38
and 7 bp products if heterozygous (AG).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All raw nanostring data are available in supplementary 1 and 2. All source data used to
generate figures are available in Supplementary Data 3. All other raw data are available
from the corresponding author upon reasonable request.
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